1. Home
  2. NGNE vs TLS Comparison

NGNE vs TLS Comparison

Compare NGNE & TLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.71

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$4.36

Market Cap

317.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
TLS
Founded
2003
1969
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
317.1M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
NGNE
TLS
Price
$20.71
$4.36
Analyst Decision
Strong Buy
Buy
Analyst Count
8
5
Target Price
$60.13
$7.90
AVG Volume (30 Days)
128.0K
926.7K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
31.51
EPS
N/A
N/A
Revenue
N/A
$164,805,000.00
Revenue This Year
N/A
$18.72
Revenue Next Year
N/A
$14.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.21
52 Week Low
$6.88
$1.83
52 Week High
$37.27
$8.36

Technical Indicators

Market Signals
Indicator
NGNE
TLS
Relative Strength Index (RSI) 48.94 50.89
Support Level $19.27 $3.80
Resistance Level $21.03 $4.69
Average True Range (ATR) 1.71 0.34
MACD -0.12 0.03
Stochastic Oscillator 39.84 34.69

Price Performance

Historical Comparison
NGNE
TLS

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

Share on Social Networks: